HeartSciences posted a net loss of $9.14 million, widening 4% from the prior year.
Operating loss edged wider to $8.41 million, while operating expenses rose 1% to $8.42 million.
Research and development expense fell 35% to $2.84 million, while selling, general and administrative costs climbed 41% to $5.58 million.
Interest expense increased 50% to $753,000.
Revenue was $4,000 with cost of sales of $2,000.
Business updates
Highlights included two commercial MyoVista Insights agreements signed in May 2026, an AI-ECG marketplace launch in June 2026, and a MyoVista wavECG 510(k) submission still under FDA review.
HSCS•
